Search clinical trials for: ASLAN001

Total 21 results

ASLAN Pharmaceuticals

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Atopic Dermatitis

Australia, Singapore, United States
ASLAN Pharmaceuticals
Iqvia Pty Ltd

Completed

Study of ASLAN004 in Healthy Subjects

Allergic Disorder

Singapore
ASLAN Pharmaceuticals

Recruiting

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Atopic Dermatitis

United States, Canada
ASLAN Pharmaceuticals

Completed

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

Stomach Neoplasms | Gastric Cancer | Gastric Neoplasms | Cancer of Stomach | Cancer of the Stomach

Korea, Republic of
ASLAN Pharmaceuticals

Completed

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

Cholangiocarcinoma

Taiwan, Korea, Republic of, Singapore
ASLAN Pharmaceuticals

Completed

A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours

Malignant Solid Tumour
National University Hospital, Singapore

Unknown

Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)

Advanced/ Metastatic Hepatocellular Carcinoma

Singapore
ASLAN Pharmaceuticals

Completed

Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003

Healthy Volunteers

Singapore
ASLAN Pharmaceuticals

Recruiting

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (FAST-AA)

Alopecia Areata

United States
ASLAN Pharmaceuticals

Completed

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Australia, Singapore
ASLAN Pharmaceuticals

Completed

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Singapore, India, Canada, New Zealand, Dominican Republic, Poland
ASLAN Pharmaceuticals

Completed

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

Gastric Cancer

Estonia, Hong Kong, Korea, Republic of, Lithuania, Malaysia, Singapore, Taiwan, Thailand
ASLAN Pharmaceuticals

Completed

A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Biliary Tract Cancer

Japan
ASLAN Pharmaceuticals

Completed

A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects

Healthy Elderly Subjects (Age ≥55 Years)

Singapore
ASLAN Pharmaceuticals
Syneos Health; bioRASI, LLC; CMIC Co, Ltd. Japan

Completed

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (TreeTopp)

Biliary Tract Cancer

United States, Australia, China, Hong Kong, Hungary, Japan, Korea, Republic of, Poland, Singapore, Spain, Taiwan
National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore; ASLAN Pharmaceuticals

Active, not recruiting

ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

Solid Tumors

Singapore
ASLAN Pharmaceuticals

Completed

Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab

Metastatic Breast Cancer

Australia, Hong Kong, Korea, Republic of, New Zealand, Philippines, Singapore, Taiwan
Asana BioSciences

Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Prostate Neoplasms, Castration-resistant

United States
National University Hospital, Singapore

Unknown

Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer

Breast Cancer

Singapore
ASLAN Pharmaceuticals

Terminated

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Biliary Tract Cancer

Taiwan, Korea, Republic of, Singapore
ASLAN Pharmaceuticals

Completed

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

Solid Tumor

Taiwan, Hong Kong

Search clinical trials for: ASLAN001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations